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Abstract  
Introduction: Pharmacotherapy with visual cycle modulators (VCMs) is under 
investigation for multiple diseases, including retinitis pigmentosa (RP), Leber congenital 
amaurosis (LCA), Stargardt macular dystrophy (SMD) and nonexudative age-related 
macular degeneration (AMD), all blinding diseases that lack effective treatment options. 
Areas Covered: Oral retinoids, including 9-cis-retinyl-acetate (Zuretinol) and 9-cis-β-
carotene, restore 11-cis-retinal levels in RP and LCA caused by LRAT and RPE65 gene 
mutations, and may improve visual acuity and visual fields. Therapies for SMD aim to 
decrease accumulation of toxic Vitamin A dimers and lipofuscin in the retina and retinal 
pigment epithelium (RPE) include C20-D3-vitamin A (ALK-001), isotretinoin, VM200 
(aldehyde trap), emixustat, and A1120. Mouse models of SMD show promising data for 
these treatments, though proof of efficacy in humans is currently lacking. Fenretinide and 
emixustat are investigational VCMs for dry AMD, though neither has been shown to 
reduce geographic atrophy or improve vision in human trials. A1120 prevents retinol 
transport into the RPE and may spare the side effects typically seen in VCMs (nyctalopia 
and chromatopsia) according to mouse studies. 
Expert Opinion: Oral VCMs may be feasible treatment options for degenerative retinal 
diseases based on pre-clinical studies. Further trials are warranted to assess their efficacy 
and safety in humans. 
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1. The Visual Cycle 
  The visual cycle refers to an enzymatic process that takes place in the outer retina 
photoreceptors and retinal pigment epithelium (RPE), in which light is converted into an 
electrical signal that is ultimately conveyed to the brain. As understanding of the visual 
cycle progresses, the ability to manipulate the visual cycle dysfunction to treat retinal 
disease is becoming a reality. 
 The rods are single photon receptors that allow visual perception in low 
illumination, while the cones are less sensitive but can distinguish various wavelengths of 
light, allowing for color vision.  Both rods and cones use 11-cis-retinal, which binds to 
opsins to then form visual pigments such as rhodopsin or cone opsins [1].  When light 
strikes rhodopsin (composed of the protein opsin bound to the chromophore 11-cis-
retinal, a vitamin A derivative) in the rod outer segments, 11-cis-retinal is converted to its 
all-trans-retinal isomer.  This, in turn, activates the opsin and initiates a signal 
transduction cascade, closing a cyclic GMP-gated cation channel, and hyperpolarizing the 
photoreceptor cell. In the visual cycle, the all-trans-retinal must be converted back to 11-
cis-retinal, via a series of steps catalyzed by enzymes, including retinol dehydrogenases 
(RDH), which catalyze reduction and oxidation reactions in the photoreceptor, as well as 
lecithin retinol acyltransferase (LRAT) and retinoid isomerohydrolase (a 65 kilodalton 
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protein, encoded by the RPE65 gene), both of which are located in the RPE [2]. The 
visual cycle is diagrammed in Figure 1, which also shows the role of select therapeutics 
that influence the visual cycle. 
 Within the visual cycle, the ATP binding cassette subfamily A member 4 (ABCA4) is localized to the outer segments of photoreceptors and acts as a membrane transporter for the recycling of chromophore during the visual cycle. Specifically, within the visual cycle, ABCA4 binds with high affinity and shuttles N-retinylidene-phosphatidylethanolamine trapped inside the photoreceptor disc across the membrane surface, where it is ultimately further processed by the adjacent retinal pigment epithelial cells.   
  The visual cycle plays a key role in several retinal disorders.  For example, 
dysfunction of enzymes in the visual cycle leads to several inherited retinal diseases 
(IRDs) such as retinitis pigmentosa (RP), Leber’s congenital amaurosis (LCA), and 
Stargardt macular dystrophy (SMD), due to the inability to either produce an adequate 
supply of 11-cis-retinal or an inability to remove the accumulation of various retinoid 
products. The visual cycle has become the focus of therapeutic strategies as several 
compounds have the potential to address defects in this cycle to treat rare IRDs.  Several 
clinical trials have utilized these visual cycle modulators in an attempt to slow the 
progression of SMD and age-related macular degeneration (AMD), the leading cause of 
irreversible blindness in the industrialized world. The drugs discussed in this review are 
summarized in Table 1. 
 
2.  Dysfunction Within the Visual Cycle and Therapies to Address Dysfunction 
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2.1. LRAT and RPE65 Dysfunction: Inherited Retinal Disease 
 Retinitis pigmentosa (RP) is the most common IRD, with a prevalence of 
approximately 1 in 3500 [3]. The term RP describes a group of genetically-heterogeneous 
progressive rod-cone retinal degenerations. Patients typically develop night blindness in 
the early phase of the disease, followed by loss of mid-peripheral visual field with 
progressive visual loss towards central vision [4].  Figure 2 shows a montage fundus 
photo of a patient with RP, which demonstrates the classic triad of optic disc pallor, 
retinal vessel attenuation, and “bone-spicule” pigmentary changes in the retinal 
periphery. 
  Leber congenital amaurosis (LCA) is a group of congenital or early onset forms 
of RP, with an autosomal recessive inheritance pattern, that occurs in approximately one 
in 81,000 births and inevitably leads to severe early visual impairment [5]. Patients with 
LCA typically have poor central and peripheral vision, early-onset nystagmus and 
severely diminished electroretinogram (ERG) responses. Figure 3 shows a montage 
fundus photo of a patient with LCA, which demonstrates retinal vessel attenuation and 
pigmentary changes similar to those seen in RP. 
 
Genes mutated in IRDs encode proteins that are involved in multiple mechanisms 
and pathways, including the phototransduction cascade (which includes the visual cycle 
described above), maintenance of photoreceptor structure, gene transcription and ciliary 
function. Mutations in more than 200 genes have been identified in IRDs. These genes 
account for only about 60% of all patients; whereas the remainder have defects in 
unidentified genes [3]. Mutations in LRAT and RPE65 are among those known to cause 
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RP and LCA [6, 7]. As noted above, RPE65 and LRAT are responsible for production 
and recycling of 11-cis-retinal and rhodopsin. Deficiencies of 11-cis retinal and 
rhodopsin cause severe rod and cone dysfunction leading to retinal degeneration and 
several visual loss [8] 
 
2.1.1  Bypass of LRAT and RPE65 Visual Cycle Defects: 9-cis-retinyl-acetate 
(QLT091001, Zuretinol) 
 In models of LRAT and RPE65-deficient mice, treatment with the chromophore 
pro-drug, 9-cis-retinyl-acetate, prevented loss of cone photoreceptors (examined 
histologically) and partially preserved the ERG b-wave compared to mice in the control 
group [9].  9-cis-retinyl-acetate combines with opsin to form isorhodopsin, which is also 
capable of starting the phototransduction cascade when activated by light [10]. 
Essentially, 9-cis-retinal administration can bypass defects in the visual cycle and 
regenerate visual pigment as isorhodopsin, thereby restoring visual function and 
ameliorating the progression of retinal degeneration in LRAT and RPE65-deficient 
animals. High doses of prolonged 9-cis-retinyl-acetate administration are well tolerated 
by the retinas of the enzyme-deficient mice, as determined by preservation of retinal 
thickness and morphology on spectral-domain optical coherence tomography (SD-OCT); 
no significant increases in fundus autofluorescence were detected at 6 months [11]. 
Batten et al demonstrated visual functions could be rescued in LRAT-deficient 
mice, as measured by recovery of levels of visual chromophore and pigment and 
improved ERG responses. Successful restoration of retinal signaling, as measured by 
pupillary responses, was also achieved.  Treatment with orally administered pro-drugs 9-
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cis-retinyl acetate and 9-cis-retinyl succinate (which chemically circumvent the LRAT-
catalyzed step in chromophore regeneration) caused enduring renewal of retinal function 
in LRAT-deficient mice and amplified ERG response from roughly 5% of wild-type 
levels in LRAT-/- mice to approximately 50% of wild-type levels in treated LRAT-/- mice.  
In the same study, the authors also showed that gene therapy with intraocular injection of 
recombinant adeno-associated virus (AAV) carrying the LRAT gene successfully 
restored ERG responses; oral and gene therapy techniques were complementary when 
combined. While full restoration of the ERG could not be obtained in LRAT-/- mice in the 
tested experimental conditions, the finding of nearly complete restoration of single cell 
responses suggests that remodeling of the neuronal retina in LRAT-/- may limit 
functional rescue [12]. 
 In a human phase 1b trial, patients with LCA or early onset RP caused by 
mutations in RPE65 (78%) or LRAT (22%) were given once daily oral 9-cis-retinyl-
acetate (also known as QLT091001 or Zuretinol acetate - developed by Novelion 
Therapeutics) 40 mg/m2/day for 7 days and many were found to have improvement in 
visual field and best-corrected visual acuity (BCVA) [13].  Eight of 18 (44%) patients 
showed a ≥20% increase and 4 of 18 (22%) showed a ≥40% increase in functional retinal 
area as measured by Goldmann visual fields (GVF). 12 (67%) and 5 (28%) of 18 patients 
showed a ≥5 and ≥10 ETDRS letter score increase of visual acuity, respectively, in one or 
both eyes at two or more visits within 2 months of treatment. The specific genotypes 
(LRAT or RPE65) did not appear to affect how patients responded to the drug [13]. There 
were no detectable improvements observed on standard electroretinography (ERG), 
similar to what has been previously observed in gene therapy trials for LCA [14-16].  
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In the same phase 1b trial, which included 14 patients with LCA caused by LRAT 
and RPE65 mutations, treatment with a 7-day course of 9-cis-retinyl-aceteate 
(QLT091001, 10-40 mg/m2) was followed by an improvement in GVF areas (mean 
increase in retinal area of 28–683%) in 10 patients (71%) for a median duration of 163 
days [16]. Patients with small to medium baseline GVF had greater improvement than 
those with a larger baseline GVF. Six patients (43%) had an improvement in visual acuity 
(mean increase of 2–30 letters) along with subjective reporting of improvement in 
activities of daily living. The median duration of the visual acuity response was 315 days 
(interquartile range: 111–534 days). After 2 years, three (21%) patients had a sustained 
GVF response and four (30%) had a sustained visual acuity response. ERG function did 
not improve in this trial, possibly due to the level of retinal degeneration already present 
at initiation of therapy. Four patients had functional MRI scans, which all correlated with 
visual response - there was increased cortical activation in one patient with increased 
GVF area, and there was no increased cortical activation in three patients that did not 
show increase in GVF area. No serious adverse events were noted, though 6 patients 
(43%) developed moderate-severe headache that resolved within 1-2 days of the last 
treatment of QLT091001, 7 patients developed moderate-severe photophobia that 
corresponded with visual improvement, and 8 patients (57%) had a transient increase in 
serum triglyceride levels [17]. 
 Measuring the outer segment length of the photoreceptor layer with SD-OCT was 
highly predictive of treatment responses, with responders having a significantly larger 
baseline outer segment thickness (11.7 ± 4.8 μm, mean ± 95% CI) than non-responders 
(3.5 ± 1.2 μm). This structure-function relationship suggests that treatment with 
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QLT091001 is more likely to be efficacious if there is sufficient photoreceptor integrity 
[13]. According to the Novelion website, 9-cis-retinyl-acetate (Zuretinol) has Orphan 
Drug designation from both the U.S. Food and Drug Administration (FDA) and European 
Medicines Agency, along with FDA Fast Track designation. [18].  
   
 
2.1.2 Bypass of LRAT and RPE65 Visual Cycle Defects: 9-cis β-carotene  
 Another randomized placebo-controlled crossover trial (NCT01256697) examined 
the effect of 9-cis-β-carotene-rich powder in patients with RP of various genotypes [19].  
Oral 9-cis β-carotene can access the retina, where it can be converted to 9-cis-retinal and 
combine with opsin to form isorhodopsin [20]. The retinoid 9-cis-retinal, which has a 
light absorption spectrum similar to that of 11-cis-retinal, can replace the latter when its 
availability is limited owing to a retinoid cycle defect.  9-cis-retinal also induces an 
increase in the endogenous production of 11-cis-retinal, as observed in mice with a 
different inborn error in the retinoid cycle [10]. Furthermore, the 9-cis β-carotene or its 
metabolites may reduce inflammation and serve as an antioxidant [21]. 
 
 29 participants completed the trial, in which they were treated daily for 90 days 
with 4 capsules each containing 300 mg of alga Dunaliella bardawil (a 9-cis-β-carotene-
rich powder, for a total approximately 20 mg of β-carotene) or placebo. The over-the-
counter Dunaliella capsules are approved by the US FDA and have been used for more 
than 20 years with no known significant adverse effects. Following a 90-day washout 
period, the groups crossed over and received treatment with the other capsule for 90 days. 
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This crossover design allows for each patient to receive both treatments, thus allowing 
each participant to serve as their own control for comparison. The primary outcome of 
the study was the dark-adapted ERG maximal b-wave response amplitude, representing 
rod and cone function objectively. The 4 secondary outcomes were light-adapted ERG b-
wave response amplitudes (objective cone function), dark adapted chromatic visual field 
area (subjective rod or cone function), conventional light-adapted visual field area 
(subjective cone and rod function), and BCVA. The measurements were obtained at 
baseline, at the end of the first 90 day treatment period, at the end of the 90 day washout 
period, and at the end of the second 90 day treatment period [19].  
 
 In 10/29 patients (34.5%, 5 patients in each group), the maximal b-wave response 
increased by more than 10 μV (range 11-42 μV) in both eyes. Relative to initial baseline, 
treatment with Dunaliella yielded a significant increase in maximal dark-adapted ERG b-
wave amplitude (+8.4 μV), whereas placebo treatment resulted in a decrease −5.9 μV 
(p=0.001). The percentage change in light-adapted b-wave response was +17.8% for 9-
cis β-carotene vs −3.0% for placebo (P = .01). Thus, both objective measures (rod and 
cone photoresponse functions) showed significant improvements after 90 days of 
Dunaliella treatment. No significant differences were found between the groups for visual 
field and BCVA. No adverse effects were observed. Based on these results, the authors 
concluded that 9-cis-β-carotene may serve as a new therapeutic approach for some 
patients with RP, possibly as an adjuvant to gene therapy. Further trials with larger 
groups of patients and a larger washout period are planned for the future [19]. 
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2.1.3  RPE65 Gene Therapy 
 Another area of research focus for LCA and RP is gene therapy to correct RPE65 
mutations. Although a comprehensive review of genetic therapy options is beyond the 
scope of this review, it is worth noting that Spark Therapeutics completed a phase 3 trial 
of its adeno-associated viral vector containing RPE65 complementary DNA (called SPK-
RPE65), which is delivered via subretinal injection. To fully assess the functional 
benefits of RPE65 gene therapy in IRD patients, a proprietary multiluminance mobility 
test (MLMT) was developed, with feedback from the FDA in order to more functionally 
assess VA, visual fields, light sensitivity, and mobility [22].  In this test, patients progress 
through a mobility test with 12 standardized templates, under multiple standardized 
lighting conditions, to determine the lowest illumination under which they can 
successfully navigate the course in under 3 minutes.  The seven levels of illumination 
reproduce the lighting conditions encountered in daily life, from 1 lux, simulating a 
moonless night, to 400 lux, simulating an office setting.  A change in score, based on 
illumination level, functions as the endpoint and has been validated.  
 Spark initiated the Phase III trial in November 2012 enrolling 31 patients with a 
mean age of 15 years; the patients were randomized 2:1 into control or receiving 1.5 x 
1011 vg of SPK-RPE65 in both eyes within 18 days. After the 12-month time point, the 
control subjects were eligible to cross over into the treatment group. In October 2015, 
Spark announced positive top-line results.  There were no serious adverse events (SAEs) 
or significant immune responses related to SPK-RPE65.  The trial met its primary 
endpoint of change at one year in the bilateral MLMT from baseline (p=0.001), with an 
average improvement 1.8 light levels in the treatment group versus 0.2 light levels in the 
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control group. Of the 20 subjects randomized to initial treatment, 13 (65%) were able to 
pass the MLMT at the lowest light level (1 lux, demonstrating maximal possible 
improvement) at one year versus none in the control group.  Secondary endpoints 
successfully met included full-field light sensitivity threshold testing (full-field scotopic 
threshold)  with 100-fold improvement in light sensitivity in treated subjects (p<0.001) 
and MLMT change score for the first injected eye (p=0.001).  There was a mean 
improvement in VA of 9 ETDRS letters, although this did not reach statistical 
significance (p=0.17) [23].  In May 2017, Spark announced that it had completed its 
rolling Biologics License Application (BLA) submission to the FDA for SPK-RPE65, 
Voretigene Neparvovec [24]. 
 Other companies that are sponsoring gene therapy trials for LCA include Applied 
Genetics Technology Corporation (AGTC) [25] and MeiraGTx.  MeiraGTx has initiated 
a phase 1 clinical trial of AAV-OPTRPE65 [26]. 
 
2.2. ABCA4 Dysfunction: Stargardt Macular Dystrophy 
 Autosomal recessive Stargardt macular dystrophy (SMD) is a dystrophy resulting 
from mutations in the ABCA4 (ABCR) gene. It is the most common form of inherited 
juvenile macular degeneration, affecting roughly in 1 in 10,000 people. Mutations in 
ABCA4 also result in RP and cone-rod dystrophy. The age of onset of juvenile and early 
adult SMD is usually 8–25 years with some cases occurring in older adults (late-adult 
onset SMD) [27, 28]. A hallmark of the disease is premature accumulation of lipofuscin 
(the “wear and tear cellular debris”) in the retinal pigment epithelium (RPE) of the eye, 
causing a pattern of yellowish flecks that extend outward from the macula (see Figure 4).  
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The brown-yellow, autofluorescent, electron-dense material is also found in cells of the 
liver, kidney, heart muscle, adrenals, nerve, and ganglion and is considered one of the 
most consistent morphologic features of aging, with a rate of accumulation inversely 
related to longevity [29, 30]. The RPE is critical for the neurosensory retina homeostasis; 
it acts as a transport exchange system with blood capillaries and is critical for 
regeneration and phagocytosis of photoreceptor outer segments. It is hypothesized that 
when RPE lipofuscin reaches a critical level, it contributes to a decline in cell function, 
resulting in the degeneration of the macular region with subsequent loss of central vision 
[31, 32].  
 
 The faulty gene in SMD, ABCA4, encodes for an outer segment rim protein 
(RmP). The function of RmP is to transport the all-trans –retinaldehyde-
phosphatidylethanolamine (retinaldehyde-PE) Schiff base from the luminal side of the 
disk membrane to the cytosolic face, where retinaldehyde can then be transformed back 
to retinol [33]. Without its functional transporter, the retinaldehyde-PE conjugates may 
react to form vitamin A dimers (including A2E and ATR-dimer), which then accumulate 
in the RPE after phagocytosis of the photoreceptors outer segments. Vitamin A dimers 
are toxic to cultured RPE cells and are thought to play a significant role in lipofuscin 
formation and subsequent retinal degeneration [34, 35]. A2E sensitizes 
RPE cells to light-induced apoptosis [36] and has an inhibitory effect on phospholipid 
turnover in RPE phagolysosomes [37]. 
 
2.2.1  Decrease Toxic Byproducts of ABCA4 Dysfunction: ALK-001 (C20-D3-
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vitamin A) 
 Kaufman and colleagues have shown that the rate determining step in vitamin A 
dimerization is the cleavage of a C20 carbon-hydrogen bond of the retinaldehyde-PE 
Schiff base [38]. Replacing the C20 hydrogen atoms of vitamin A with deuterium atoms 
(i.e. C20-D3 -vitamin A) makes this bond harder to cleave and impedes vitamin A 
dimerization. Several studies have sought to determine whether slowing the intrinsic 
reactivity of vitamin A to dimerize could slow lipofuscin formation in the RPE and delay 
changes associated with human SMD. Ma and colleagues raised ABCA4-/- mutant albino 
mice (the mouse model of human SMD) on diets containing either C20-D3 –vitamin A 
(the treated group) or vitamin A at its natural isotopic abundance (the control group) and 
measured the concentration of vitamin A dimers, lipofuscin and other biological markers 
indicative of ocular health in both groups. Treated mice exhibited an 80% reduction in 
A2E, a 95% reduction in ATR dimer and a 70% decrease in fundus autofluorescence at 
three months of age. After six months, the treated group showed fewer lipofuscin 
granules as visualized qualitatively by electron microscopy, and at 12 months they 
showed improved eye function as measured by ERG. These results suggest that 
pathological phenotypes that arise from defects in the ABCA4 gene may result from the 
dimerization of vitamin A and may be improved by hindering the ability of vitamin A to 
dimerize [39].  
 Similar results were found in another mouse model of SMD, in which Vitamin A 
dimerization contributed to over 50% of lipofuscin accumulation and caused 
transcriptional dysregulation of several complement genes associated with inflammation 
[40]. Replacing Vitamin A with C20-D3-vitamin A impeded dimerization of Vitamin A 
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(by approximately fivefold for A2E), and additionally normalized the aberrant 
transcription of complement genes without impairing retinal function. Phenotypic rescue 
by C20-D3-vitamin A was also observed noninvasively by quantitative autofluorescence 
in as little as 3 months after the initiation of treatment, whereas upon interruption of 
treatment, the age-related increase in autofluorescence resumed. These results further 
indicate that administration of C20-D3 -vitamin A may be a feasible therapeutic approach 
to slow the progression of associated retinal disease caused by Vitamin A dimerization. 
During these mice studies, no side effects were noted, and the animals were administered 
the drug for 12 months. 
 The promising results of the aforementioned pre-clinical studies have paved the 
way for the oral once-daily C20-D3-vitamin A molecule, ALK-001 (Alkeus 
Pharmaceuticals, Boston, MA), to begin human clinical trials in SMD. A Phase 1 trial 
(NCT02230228) to assess the safety and pharmacokinetics in healthy volunteers has been 
completed [41]. The phase 2 TEASE study (NCT02402660) is ongoing [42].  
 
2.2.2  Decrease Toxic Byproducts of ABCA4 Dysfunction:  VM200 
 Vision Medicine’s VM200 molecule for SMD is currently in pre-clinical trials. 
This oral drug sequesters the toxic compound, all-trans retinal, to prevent retinal cell 
death [43].  Specifically, VM200 is a primary amine that reacts with the aldehyde group 
of all-trans retinal to form an inactive Schiff base, thus making it unable to form A2E. 
VM200 was shown to preserve retinal structure in ABCA4-/- Rdh8-/- mice, as measured 
by SD-OCT. According to unpublished data from Case Western Reserve University, 
VM200 has also demonstrated ability to preserve retinal function, as mice treated with it 
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were noted to have increased concentration of 11-cis retinal (a biomarker of intact 
photoreceptors) compared to controls [44]. No significant toxicities were noted in 2-week 
and 13-week long studies. The molecule of VM200 is an enantiomer of pregabalin, which 
is used to treat neuropathic pain, though its affinity for the pregabalin target is 10-fold 
less than that of pregabalin. VM200 is also indicated for other inborn errors of aldehyde 
metabolism including Sjogren-Larsson Syndrome, Best Disease, and Succinic 
semialdehyde-dehydrogenase deficiency. Pre-clinical studies are continuing [44].  
 
2.2.3  ABCA4 Gene Therapy 
 Gene therapy is also being explored to treat SMD. The ABCA4 gene (6.8 kb) far 
exceeds the 4.5-5.0 kb capacity of the AAV vector and has required utilization of an 
equine infectious anemia lentivirus (EIAV) for gene transfer [45]. Subretinal injection of 
EIAV-ABCA4 was found to be effective in a knock out mouse model and the StarGen 
(Sanofi) gene replacement lentivector carrying the ABCA4 gene is currently in Phase 1/2 
trials [46] [47]. 
 
3 Therapeutic Inhibition of the Visual Cycle 
3.1 11-cis-retinol dehydrogenase 
3.1.1. Isotretinoin 
 Isotretinoin (Accutane) is a drug that is used to treat acne, but has also been 
shown to inhibit lipofuscin formation in a mouse model [48]. It works by inhibiting 11-
cis-retinol dehydrogenase in the visual cycle, thus slowing the synthesis of 11-cis-
retinaldehyde and regeneration of rhodopsin. This explains the side effect of decreased 
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night vision in patients who use isotretinoin for acne [49] , though isotretinoin has not 
been shown to induce photoreceptor degeneration, and actually protects against light-
induced damage [50]. Light activation of rhodopsin results in its release of all-trans-
retinaldehyde, which constitutes the first reactant in toxic A2E biosynthesis. ABCA4-/-  
mice that were injected with isotretinoin had decreased production of A2E, along with 
less formation of lipofuscin granules in the retina compared to controls, as viewed by 
electron microscopy. Additionally, wildtype mice treated with isotretinoin for 2 months 
had a 40% reduction of A2E formation in the RPE compared to controls. On ERG, both 
wild-type and ABCA4-/- mice showed smaller delays in dark adaptation after isotretinoin 
administration with bright compared with dim probe flashes. These results suggest that 
isotretinoin reduced rhodopsin levels in both wild-type and ABCA4-/- retinas. The authors 
propose that isotretinoin may delay visual loss in SMD and other retinal diseases linked 
to lipofuscin accumulation. 
 
3.2 RPE65 3.2.1 Emixustat. 
 Emixustat (ACU-4429, developed by Acucela Inc) is a small non-retinoid 
derivative of retinylamine that inhibits RPE65, thus reducing the conversion of all-trans-
retinyl ester to 11-cis-retinol and preventing accumulation of A2E. Phase 1 studies 
showed that the drug was well-tolerated up to 75 mg with expected dose dependent 
suppression of scotopic ERG in healthy subjects [51].  It was initially developed to slow 
the progression of geographic atrophy in age-related macular degeneration (AMD), but it 
also being tested for SMD. 
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  AMD is the leading cause of irreversible legal blindness in people ≥ 65 years of 
age in the Western world, affecting over 1.7 million people in the United States and 
expected to reach almost 3 million by 2020 [52]. AMD is classified into one of two 
general subgroups: the non-neovascular (non-exudative or dry) form of the disease and 
the neovascular (exudative or wet) form of the disease.  The non-neovascular form of 
AMD accounts for approximately 90% of all AMD cases, and is often characterized by a 
slow degeneration of the macula, resulting in atrophy of the central macula with gradual 
vision loss over a period of years.  In contrast, neovascular AMD (nAMD), although less 
prevalent, commonly causes sudden and often substantial loss of central vision, 
accounting for most cases of severe vision loss in this disease.  This type of AMD is 
characterized by the growth of pathologic choroidal neovascularization (CNV) beneath 
the macula, which causes exudation of blood and/or fluid into the macula.  Ultimately, 
neovascular tissue and associated exudates develop into a destructive macular scar, 
leading to central blindness.  
 The advanced stage of dry AMD, geographic atrophy (GA), is characterized by 
loss of retinal photoreceptors, RPE, and choriocapillaris, and is responsible for 
approximately 20% of all cases of legal blindness in North America. Currently, the major 
unmet need in AMD is there is no available treatment for GA. Figure 5 shows a color 
fundus photo of a patient with GA, which demonstrates a patch of atrophic retina and 
RPE, with prominent underlying choroidal vessels visible in the macula. 
 One strategy for the treatment of GA is the interruption of the visual cycle by 
reducing the accumulation of toxic metabolites, A2E and lipofuscin,  Acucela launched 
its Phase 2 clinical trial of emixustat in patients with dry AMD in January 2010. In March 
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2010, emixustat was granted Fast Track status by the U.S. FDA for the treatment of dry 
AMD. In this 90-day, dose-escalation safety study, 72 subjects with GA received either 
emixustat (2, 5, 7, or 10 mg in the morning or 5 mg in the evening) or placebo once per 
day. 54 subjects received emixustat and 18 received placebo. Approximately four hours 
after subjects were given either emixustat or placebo, and following pupil dilation and 
dark adaptation, ERG measurements were recorded at multiple time points after three 
minutes of exposure to a bright, bleaching light. Rod photoreceptor b-wave sensitivity 
was suppressed in a dose-dependent manner in subjects receiving emixustat, as measured 
by ERG, for doses up to 10 mg (range 26% - 89% suppression of b-wave in the 2 mg and 
10 mg groups respectively). This effect was reversible, as the post-bleach mean b-wave 
amplitudes returned to baseline 7-14 days after treatment, with exception of the 10 mg 
group, whose results were influenced by an outlier. There was no significant effect of 
emixustat on the cone photoresponse as measured by single flash or 31-Hz flicker ERG. 
Ocular adverse events were noted in a dose-dependent manner, and included 
chromatopsia (57% of emixustat group) and delayed dark-adaptation (48% of emixustat 
group). 85% of these adverse events resolved within 7-14 days of discontinuing 
emixustat [53]. 
 
 In May 2016, Acucela announced the results of its Phase 2b/3 “S.E.A.T.T.L.E.” 
clinical trial. This study enrolled 508 patients with GA due AMD and sought to 
demonstrate that emixustat could reduce the growth rate of GA compared to placebo. 
The lesion growth rates over 24 months for the 10 mg, 5 mg, 2.5 mg and placebo groups 
were 1.84 mm2/year, 1.83 mm2/year, 1.69 mm2/year, and 1.69 mm2/year, respectively. 
The study failed to meet its primary endpoint, as there was no statistically significant 
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difference in lesion growth rate for any treatment group compared to placebo. There was 
no significant difference in the mean change of BCVA from baseline to month 24 
between treatment groups. There was a small numerical treatment difference observed in 
certain patients with specific genetic profiles in favor of emixustat. The profile of adverse 
events was similar to that of earlier trials [54]. Acucela has broadened its scope to testing 
emixustat as treatment for SMD, and approximately 30 patients are enrolled in a phase 2a 
study that will take place in the United States [53].   
 
3.3 Vitamin A Transport 
3.3.1 Fenretinide  
 Fenretinide (Sirion Therapeutics) is an oral synthetic retinoid derivative that 
competes with retinol to bind with retinol-binding protein 4 (RBP4), thus preventing 
transport of retinol into the RPE.  Serum retinol is maintained in circulation as a tertiary 
complex with RBP4 and transthyretin (TTR). Reduction in delivery of retinol-RBP-TTR 
to the RPE is thought to decrease accumulation of A2E and potentially slow the rate of 
GA growth. Once fenretinide binds to RBP, the RBP-fenretinide complex is rapidly 
eliminated in the urine [55].  Fenretinide has been shown to reduce formation of A2E in a 
mouse model of SMD [56]. Possible downsides to fenretinide therapy include its 
tendency to induce apoptosis in many cell types (including RPE) [57], along with 
teratogenic effects that would limits its use in women of child-bearing age (more 
pertinent in treating SMD than AMD) [58]. 
 A recent phase 2 study assessed fenretidine (100 and 300 mg orally administered 
daily versus placebo) for slowing lesion growth in 246 patients with GA.  There was a 
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dose-dependent reduction of serum RBP in fenretinide-treated patients.  There was also a 
trend for reduced annual lesion growth rates in patients in the 300 mg fenretinide group 
who achieved serum retinol levels of ≤1µM (1.70 mm2/year vs. 2.03 mm2/year, mean 
reduction of 0.33 mm2 compared to placebo, p = 0.1848). Only 51% of patients receiving 
300 mg and completing the 2-year study achieved this level of serum retinol reduction, 
resulting in a non-significant change in lesion growth rate versus the placebo group. RBP 
reductions < 2 mg/dL correlated with further reductions in lesion growth rates (r2= 
0.478). There was a 45% reduction in CNV formation among fenretinide groups, though 
all groups in the study lost a mean of 10-11 letters of vision at 2 year follow up, 
consistent with the natural history of GA and suggesting no visual benefit to the modest 
reduction in GA growth [59]. The 300 mg fenretinide group had 20.2% of patients 
withdraw from the study due to adverse effects, though only complaints related to the 
skin or eye were thought to be drug related. The most common ocular adverse events that 
were reported (but did not necessarily lead to study withdrawal) included decreased 
visual acuity (71 %), night blindness (37.3 %), and visual disturbance (26.5 %).    
   
3.3.2 A1120  
 A1120 (ICR-14967) is another drug that aims to lower serum retinol levels to 
treat AMD and SMD. It was originally developed as a potential treatment for diabetes. 
Like fenretinide, A1120 is a RBP4 antagonist, though A1120 differs in that it is not a 
retinoid and not an agonist to Retinoic Acid Receptor-alpha. This property may spare 
patients from the side effect profile associated with retinoids, which includes nyctalopia 
and delayed dark adaptation. ABCA4 -/- mice that were administered A1120 30 mg/kg 
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daily for 6 weeks were found to have a 75% reduction of serum RBP4 along with 50% 
reduction of lipofuscin bisretinoids compared to the control group. On ERG testing, no 
statistically significant difference in kinetics of the b-wave recovery after photobleaching 
was found between the groups of A1120- and vehicle-treated wild-type animals, 
suggesting that A1120's capacity for reduction of lipofuscin bisretinoids in the retina may 
not be associated with the appreciable suppression of the visual cycle. This finding 
supports the notion that A1120 is unlikely to cause side effects of nyctalopia or delayed 
dark-adaptation, which is seen in the other visual cycle modulators [60]. Based on this 
preclinical data, clinical trials are under development by a collaborative effort between 
iCura Vision, Columbia University, and the National Institutes of Health [60].  
 
5. Conclusion  
 Pharmacological modulation of the visual cycle serves as a novel approach to the 
treatment of degenerative retinal diseases. Four classes of therapeutics, which work by 
inhibiting vitamin A dimer and lipofuscin accumulation in the retina, are emerging as 
potential treatments for SMD and AMD. These include direct inhibitors of key visual 
cycle enzymes (isotretinoin and emixustat), RBP4 antagonists (fenretinide and A1120), 
primary amine-containing aldehyde traps (VM200), and deuterated analogs of vitamin A 
(ALK-001). For treatment of RP and LCA, 9-cis-retinyl acetate (zuretinol) and alga 
Dunaliella bardawil aim to bypass inherited defects in RPE65 and LRAT function in 
order to regenerate the visual chromophore 11-cis-retinal, thus allowing the next photon 
of light to initiate the next visual cycle. 
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6. Expert Opinion (500-1000 words) 
  
 The pathophysiology of AMD is very complex and not fully elucidated, and 
would thus require a multi-targeted approach to maximally halt the disease process. 
Oxidative damage, chronic inflammation, malfunction of the complement system, beta-
amyloid deposition, and lipofuscin accumulation are all thought to contribute to AMD 
progression to varying degrees. For this reason, several different classes of medications 
are being tested to target these pathways, including mammalian target of rapamycin 
(mTOR) inhibitors, complement inhibitors, matrix metalloproteinase inhibitors, low-
density lipoprotein (LDL)-lowering drugs, anti-amyloid beta drugs, antioxidants, 
neuroprotectants, choroidal perfusion enhancers, neurotrophins, and stem cell therapy 
[61]. Visual cycle modulation is just one piece of this convoluted puzzle, and many 
questions remain regarding its efficacy in slowing progression of GA. The emixustat and 
fenretinide trials both failed to show a statistically significant improvement in GA 
progression or BCVA, while also causing a notable amount of ocular and non-ocular side 
effects.  
 For management of both SMD and AMD, A1120 may one day serve as an 
intriguing option, as its developer suggests that it may not be associated with mechanism-
based ocular side effects typical for direct visual cycle inhibitors, such as nyctalopia and 
delayed dark-adaptation [62]. However, given that it has only been tested in mouse 
models of SMD, it is too soon to speculate about its efficacy in humans. Aldehyde 
trapping (VM200) could also represent an appealing approach to inhibiting retinal 
bisretinoid formation, as it may also lack the mechanism-based ocular side effects typical 
for direct visual cycle inhibitors. However, the compounds may need to be administered 
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at very high systemic doses to act as aldehyde traps in the retina, which raises safety 
concerns. Local retinal delivery may be considered as an alternative to systemic 
administration of aldehyde traps to overcome potential systemic toxicities [62].  
 Isotretinoin, which has been used as an acne treatment for many years with an 
acceptable safety proposal (aside from teratogenicity), has shown some promise in 
reducing lipofuscin formation in mouse models of SMD, but there is a paucity of data to 
confirm its beneficial effect on humans with SMD at this point in time. C20-D3-vitamin 
A (ALK-001) has shown similarly impressive results in reducing accumulation of 
Vitamin A dimers and lipofuscin in the retina, along with improved ERG function in 
Stargardt mouse models, though the results of the completed phase 1 trial have not been 
released, to the best of the authors’ knowledge. 
  There are many different genetic mutations that may cause RP and LCA, so much 
like AMD, there is no one-size-fits-all treatment for this group of diseases. Modulation of 
the visual cycle with retinoids such as 9-cis-retinyl-acetate (zuretinol) and 9-cis-β-
carotene may help those patients with mutations in LRAT or RPE65. Human trials, while 
limited in sample size, have demonstrated that some RP and LCA patients taking 
zuretinol have shown improvements in visual field and visual acuity. However, given that 
over 100 genes account for about 70% of RP patients while the remainder have unknown 
mutations [3], it is likely that only a small subset of patients would be candidates for the 
therapies mentioned in this article. Given the recent success of viral vector gene therapy 
for LCA, it will be interesting to see if oral retinoids will have a supplementary role in 
patients with LCA who opt for gene therapy, or if pharmacotherapy will be bypassed 
altogether. 
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Article Highlights Box  
• Degenerative retinal diseases such as dry age-related macular degeneration 
(AMD), retinitis pigmentosa (RP), Leber’s congenital amaurosis (LCA), and 
Stargardt macular dystrophy  (SMD) may cause blindness and currently lack 
effective therapies. 
• Oral retinoid therapies such as 9-cis-retinyl and 9-cis-β-carotene may help to 
restore 11-cis-retinal levels in cases of RP and LCA caused by mutations in 
LRAT and RPE65. Phase 3 clinical trial data will be needed to definitively 
determine improvements in visual acuity and visual fields. 
• Oral therapies for SMD aim to decrease accumulation of Vitamin A dimers and 
lipofuscin in the retina and RPE, and include ALK-001, isotretinoin, VM200, 
emixustat, and A1120. There is an abundance of data that shows efficacy of these 
treatments in mouse models of SMD, though evidence of efficacy in humans is 
currently lacking.  
• Visual cycle suppression is associated with nyctalopia, delayed dark-adaptation, 
and dyschromatopsia. 
• Fenretinide, emixustat and A1120 are visual cycle modulators (VCMs) under 
investigation for Dry AMD, though none of them has been shown to reduce 
geographic atrophy or improve vision in humans. 
•  Gene therapy with viral vectors is being explored as another option in treating 
RP, LCA, SMD, and AMD. 
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Figure Legends: 
Figure 1. The visual cycle pathway begins when light (starburst shape) interacts with 
rhodopsin (diamond shape), setting off a series of steps catalyzed by enzymes (cloud 
shapes). The chemical byproducts and investigational drugs are represented in box and 
oval shapes, respectively. The cross-through symbol denotes an inhibitory effect of a 
drug on the enzymes, while a plus sign indicates the effect of increasing rhodopsin levels.   
RDH = retinol dehydrogenase, ABCA4 = ATP-Binding Cassette Subfamily A Member 4, 
LRAT = lecithin retinol acyltransferase, RPE = retinal pigment epithelium. 
 
Figure 2. Montage fundus photo of a patient with retinitis pigmentosa, which 
demonstrates the classic triad of optic disc pallor, retinal vessel attenuation, and “bone-
spicule” pigmentary changes in the retinal periphery 
 
Figure 3. Montage fundus photo of a patient with Leber’s congenital amaurosis, which 
demonstrates retinal vessel attenuation and pigmentary changes similar to those seen in 
RP. 
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Figure 4. Fundus photography of a patient with Stargardt macular dystrophy shows 
yellowish flecks (representing lipofuscin accumulation in the RPE) that extend outward 
from the macula. 
 
Figure 5. Fundus photography of a patient with age-related macular degeneration with 
geographic atrophy, which highlights the atrophic appearance of the retina and RPE in 
the macula, leading to increased prominence of the underlying choroidal vasculature. 
 
Table 1.  Summary of the investigational drugs in development to treat inherited and age-
related degenerative diseases of the retina. 
Medication Chemical Structure Mechanism of action Indication Company  Stage of development  
QLT091001 
(Zuretinol) 9-cis-retinyl-acetate 
Combines with opsin to form 
isorhodopsin, thus bypassing defects in 
the visual cycle RP/LCA 
Novelion 
Therapeutics Phase 3 trials 
Alga Dunaliella 
bardawil 9-cis β-carotene  
9-cis β-carotene is converted to 9-cis-
retinal in the retina, which then 
combines with opsin to form 
isorhodopsin RP 
Available as generic 
OTC supplement Approved by US FDA 
ALK-001 C20-D3 -vitamin A 
Replacing the C20 hydrogen atoms of 
vitamin A with deuterium atoms makes 
cleavage of the carbon-hydrogen bond 
more difficult, thereby reducing Vitamin 
A dimerization and lipofuscin 
Stargardt 
disease 
Alkeus 
Pharmaceuticals Phase 2 trials 
Isotretinoin 13-cis-retinoic acid 
Inhibits 11-cis-retinol dehydrogenase, 
thus slowing the synthesis of 11-cis-
retinaldehyde and regeneration of 
rhodopsin.  
Stargardt 
disease 
available in generic 
form Pre-clinical trials 
VM200 
enantiomer of 
pregabalin 
Aldehyde trap (reacts with toxic all-tran-
retinal to form inactive schiff base) 
Stargardt 
disease Vision Medicine Pre-clinical trials 
ACU-4429 
(Emixustat) 
non-retinoid derivative 
of retinylamine 
Inhibits RPE65, thus reducing the 
conversion of all-trans-retinyl ester to 
11-cis-retinol and preventing 
accumulation of A2E.  
AMD/Stargardt 
disease Acucela Inc 
AMD: Phase 2b/3 trial 
did not meet endpoint. 
Stargardt disease: Phase 
2a trial enrolling  
Fenretinide 
synthetic retinoid 
derivative, "N-(4-
hydroxyphenyl)retinam
ide"  
RBP4 antagonist that  prevents transport 
of retinol into the RPE AMD Sirion Therapeutics 
Phase 2 trial did not 
meet primary endpoint 
A1120 (ICR-
14967) 
2-(4-[2-
(trifluoromethyl)phenyl
]piperidine-1-
carboxamido)benzoic 
acid 
Nonretinoid RBP4 antagonist that  
prevents transport of retinol into the RPE 
AMD/Stargardt 
disease iCura Vision 
Clinical trials in 
development  
Rhodopsin All-Trans-Retinal
RDH, ABCA4
(Photoreceptor)
All-Trans-Retinol
LRAT
(RPE)
All-Trans-Retinyl Ester
Retinoid 
Isomerohydrolase
(RPE)
11-Cis-Retinol
RDH
(Photoreceptor)
11-Cis-Retinal

 
+ Light
VM200
9-cis-
retinoids 
Isotretinoin
Emixustat
